BRIAN P. MCKEON - 10 Feb 2024 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
Director
Signature
/s/ Shantale Greenson, attorney-in-fact for Brian P. McKeon
Issuer symbol
ALKS
Transactions as of
10 Feb 2024
Net transactions value
+$6,575
Form type
4
Filing time
13 Feb 2024, 17:11:16 UTC
Previous filing
09 Feb 2024
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +4,533 +23% 24,229 10 Feb 2024 Direct F1
transaction ALKS Ordinary Shares Tax liability $29,724 -1,088 -4.5% $27.32 23,141 10 Feb 2024 Direct
holding ALKS Ordinary Shares 10,000 10 Feb 2024 by Brian P. McKeon Trust F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $2,023 +90 +2% $22.48 4,639 17 Nov 2023 Ordinary Shares 90 $22.48 Direct F3, F4
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $11,757 +523 +2% $22.48 26,692 17 Nov 2023 Ordinary Shares 523 $22.48 Direct F3, F4
transaction ALKS Restricted Stock Unit Award Other +88 +2% 4,533 17 Nov 2023 Ordinary Shares 88 Direct F1, F3, F5
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $7,587 +313 +2% $24.24 15,990 17 Nov 2023 Ordinary Shares 313 $24.24 Direct F3, F4
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $7,129 +231 +2% $30.86 11,785 17 Nov 2023 Ordinary Shares 231 $30.86 Direct F3, F4
transaction ALKS Non Qualified Stock Option (Right to Buy) Other $7,803 +254 +2% $30.72 12,986 17 Nov 2023 Ordinary Shares 254 $30.72 Direct F3, F6
transaction ALKS Restricted Stock Unit Award Other +119 +2% 6,104 17 Nov 2023 Ordinary Shares 119 Direct F1, F3, F7
transaction ALKS Restricted Stock Unit Award Options Exercise -4,533 -100% 0 10 Feb 2024 Ordinary Shares 4,533 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 The reporting person and his wife are trustees of The Brian P. McKeon Revocable Trust, dated April 12, 2007 and amended and restated on February 8, 2019 (the "Brian P. McKeon Trust"), and members of the reporting person's immediate family are beneficiaries of the trust.
F3 Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.
F4 These options are fully vested in accordance with their terms.
F5 This award is fully vested in accordance with its terms.
F6 Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.
F7 Shares subject to the restricted stock unit award vest in full on 6/29/2024.

Remarks:

EXHIBIT LIST: Exhibit 24.1 - Power of Attorney